Structure-Affinity Relationships and Structure-Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A(3) Receptor Antagonists by Xia, L. et al.
Structure−Aﬃnity Relationships and Structure−Kinetics
Relationships of Pyrido[2,1‑f ]purine-2,4-dione Derivatives as Human
Adenosine A3 Receptor Antagonists
Lizi Xia, Wessel A. C. Burger, Jacobus P. D. van Veldhoven, Boaz J. Kuiper, Tirsa T. van Duijl,
Eelke B. Lenselink, Ellen Paasman, Laura H. Heitman, and Adriaan P. IJzerman*
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, The Netherlands
*S Supporting Information
ABSTRACT: We expanded on a series of pyrido[2,1-f ]purine-2,4-dione derivatives as human adenosine A3 receptor (hA3R)
antagonists to determine their kinetic proﬁles and aﬃnities. Many compounds showed high aﬃnities and a diverse range of
kinetic proﬁles. We found hA3R antagonists with very short residence time (RT) at the receptor (2.2 min for 5) and much longer
RTs (e.g., 376 min for 27 or 391 min for 31). Two representative antagonists (5 and 27) were tested in [35S]GTPγS binding
assays, and their RTs appeared correlated to their (in)surmountable antagonism. From a kon−koff−KD kinetic map, we divided the
antagonists into three subgroups, providing a possible direction for the further development of hA3R antagonists. Additionally,
we performed a computational modeling study that sheds light on the crucial receptor interactions, dictating the compounds’
binding kinetics. Knowledge of target binding kinetics appears useful for developing and triaging new hA3R antagonists in the
early phase of drug discovery.
■ INTRODUCTION
The adenosine A3 receptor is the youngest member discovered
in the family of adenosine receptors,1 all of which belong to
class A G-protein coupled receptors (GPCRs) and fall into four
distinct subtypes (A1, A2A, A2B, and A3). Although all subtypes
are activated by the endogenous ligand adenosine, these
purinergic receptors diﬀer from each other in their distribution
and to which G protein they are coupled. Following agonist
activation, the A1 and A3 adenosine receptors cause a decrease
in cAMP levels as they primarily couple to Gi proteins. The A2A
and A2B adenosine receptors, on the other hand, are primarily
linked to Gs proteins, and this leads to increased levels of cAMP
upon receptor activation.2
Although the pharmacological characterization of adenosine
receptors has been well documented,3 the human adenosine A3
receptor (hA3R) is less well characterized because of its
“dichotomy” in diﬀerent therapeutic applications.4 Moreover,
certain ligands have been described as cytoprotective or
cytotoxic merely depending on the concentration employed,
highlighting the diﬃculties that arise when characterizing novel
hA3R compounds.
5 Nevertheless, there is no doubt that the
hA3R has therapeutic potential in clinical indications (i.e.,
cardiovascular diseases,6,7 cancer,7,8 and respiratory dis-
eases7,9−11) due to its overexpression on cancer and
inﬂammatory cells.3,12−15
Traditional drug screening methods, and those employed in
previous hA3R drug discovery attempts, revolve around the use
of a ligand’s aﬃnity as the selection criterion for further
optimization in a so-called structure−aﬃnity relationships
(SAFIRs) approach. In recent years, however, there has been
emerging the realization that selecting ligands based on their
aﬃnity, an equilibrium parameter, does not necessarily predict
in vivo eﬃcacy. This is due to the dynamic conditions in vivo
that often are in contrast to the equilibrium conditions applied
in in vitro assays.16 In fact, a ligand’s kinetic properties may
provide a better indication of how a ligand will perform in
vivo.17 Speciﬁcally, the parameter of residence time (RT) has
been proposed as a more relevant selecting criterion. The RT
reﬂects the lifetime of the ligand−receptor complex and can be
calculated as the reciprocal of the ligand’s dissociation constant
(RT = 1/koff).
18,19
While the binding kinetics of some (labeled) hA3R agonists
have been studied,20 this parameter has not been part of
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medicinal chemistry eﬀorts for antagonists, i.e., yielding
structure−kinetics relationships (SKRs), next to SAFIRs.21
Therefore, to provide the ﬁrst SKR analysis on the hA3R, a
highly potent and selective hA3R antagonist scaﬀold was
chosen. The pyrido[2,1-f ]purine-2,4-dione template has been
previously characterized with respect to aﬃnity alone. In a
Topliss approach,22 we had synthesized and characterized a
number of highly potent and selective hA3R antagonists.
23,24
One of the reference antagonists (1) with good aﬃnity and
selectivity over other adenosine receptors is represented in
Table 1. Using this compound as the starting point, we further
selected and synthesized compounds to add to the library of
pyrido[2,1-f ]purine-2,4-dione derivatives. Using radioligand
displacement assays and competition association assays, we
obtained aﬃnity (Ki) and kinetic parameters (kon, koff, and
RTs). This allowed a full SKR study alongside a more
traditional SAFIR analysis. The ﬁndings provide information on
the structural requirements for a favorable kinetic proﬁle at the
hA3R and consequently may improve the in vitro to in vivo
translation for hA3R antagonists.
■ RESULTS AND DISCUSSION
Chemistry. The synthesis approach shown in Scheme 1 was
adapted from Priego et al.23,24 Starting from the commercially
available materials benzylurea (3), ethyl cyanoacetate, and
sodium methoxide. 1-benzyl-6-amino-uracil (4) was synthe-
sized in an 88% yield.25 In situ dibromination of uracil 4 at the
C5 position by N-bromosuccinimide, followed by cyclization
with 4-methoxypyridine, gave the pyrido[2,1-f ]purine-2,4-
dione (5) in a one-pot reaction. Final compounds 1, 2, and
6−22 (as depicted in Table 1) were obtained, with yields
varying in the range of 3−86%, by alkylating the N3 position of
5 using a variety of alkyl, alkenyl, and alkynyl bromides in
acetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) as a
base. Second, to be able to diversify on the N1 (R2) position,
building block 23 had to be obtained. Full conversion of
methylcyclopropyl compound 2 into the desired debenzylated
23 was realized by multiple additions of ammonium formate
and Pd(OH)2 at 80 °C in ethanol overnight. Because of poor
solubility, 23 was extracted with hot DMF and Pd(OH)2 was
removed by ﬁltration, resulting in a quantitative yield. Finally,
various N1 substituted benzyl (24−32) and phenethyl (33)
derivatives (Scheme 1) were made starting from the respective
benzyl- or phenethyl bromides in DMF with K2CO3 used as
base.
Biological Evaluation. All binding aﬃnities of the
pyrido[2,1-f ]purine-2,4-dione derivatives were determined at
25 °C in a 2 h incubation protocol. All compounds were able to
concentration-dependently inhibit speciﬁc [3H]8-ethyl-4-meth-
yl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H- imidazo[2,1-i]-purin-
5-one26 ([3H]PSB-11, 34) binding to the human adenosine
A3 receptor, and their aﬃnities are listed in Tables 1, 2 and 3.
Table 1. Binding Aﬃnity and Kinetic Parameters of 1-Benzyl-8-methoxy-3-propylpyrido[2,1-f ]purine-2,4(1H,3H)-dione23,24
compd pKi
a ± SEM (mean Ki in nM) KRI
b kon
c (M−1 s−1) koff
d (s−1) RTe (min)
1 8.5 ± 0.02 (3.2) 0.99 (0.97, 1.0) (8.5 ± 1.2) × 105 (3.2 ± 0.02) × 10−4 52 ± 0.3
apKi ± SEM (n ≥ 3, average Ki value in nM), obtained at 25 °C from radioligand binding assays with [3H]34 on human aenosine A3 receptors stably
expressed on CHO cell membranes. bKRI (n = 2, individual estimates in parentheses), obtained at 10 °C from dual-point competition association
assays with [3H]34 on human aenosine A3 receptors stably expressed on CHO cell membranes.
ckon ± SEM (n ≥ 3), obtained at 10 °C from
competition association assays with [3H]34 on human aenosine A3 receptors stably expressed on CHO cell membranes.
dkoff ± SEM (n ≥ 3),
obtained at 10 °C from competition association assays with [3H]34 on human aenosine A3 receptors stably expressed on CHO cell membranes.
eRT
(min) = 1/(60 × koff).
Scheme 1. Synthesis of 1,3-Disubstituted-1H,3H-pyrido[2,1-f ]purine-2,4-dione Derivativesa
a(a) ethyl cyanoacetate, NaOEt, EtOH, reﬂux, overnight; (b) (i) NBS, CH3CN, 80 °C, 1 h, (ii) 4-methoxypyridine, 80 °C, overnight; (c) R1-Br,
DBU, CH3CN, 80 °C, overnight; (d) 20% Pd(OH)2, ammonium formate, EtOH, reﬂux, overnight; (e) R2-Br, K2CO3, DMF, 40 °C, overnight.
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All compounds had (sub)nanomolar binding aﬃnities ranging
from 0.38 nM for compound 27 to 108 nM for compound 5.
Subsequently, the human adenosine A3 receptor ligands were
screened in a so-called “dual-point” competition association
Table 2. Binding Aﬃnities and Kinetic Parameters of Pyrido[2,1-f ]purine-2,4-dione Derivatives with Modiﬁcation on N-3
Position (R1 Group)
compd R1 pKi
a ± SEM (mean Ki in nM) KRI
b kon
c (M−1 s−1) koff
d (s−1) RTe (min)
5 H 7.0 ± 0.02 (108) 0.38 ± 0.12 (5.3 ± 1.5) × 105 (1.4 ± 0.5) × 10−2 2.2 ± 1.4
6 CH3 7.7 ± 0.1 (20.8) 0.54 (0.52, 0.55) nd
f nd nd
7 CH2CH3 8.0 ± 0.1 (10.7) 0.80 (0.85, 0.75) nd nd nd
8 CH2CH2CH2CH3 8.8 ± 0.1 (1.5) 1.29 (1.27, 1.31) nd nd nd
9 CH2CH2CH2CH2CH3 8.5 ± 0.02 (3.5) 1.11 (0.98, 1.24) (1.1 ± 0.1) × 10
6 (6.0 ± 0.5) × 10−4 28 ± 2.2
10 CH2CH2CH2CH2CH2CH3 8.6 ± 0.1 (2.8) 2.18 (2.15, 2.21) (2.3 ± 1.0) × 10
5 (8.2 ± 1.3) × 10−5 213 ± 35
11 CH2CH2CH2CH2CH2CH2CH3 8.2 ± 0.2 (6.8) 4.06 (3.66, 4.46) (4.2 ± 0.3) × 10
5 (6.2 ± 0.2) × 10−5 278 ± 45
12 CH2CHCH2 8.3 ± 0.1 (5.9) 0.72 (0.46, 0.99) nd nd nd
13 CH2CCH 8.4 ± 0.02 (4.3) 1.20 (1.16, 1.23) nd nd nd
14 CH2CH2CHCH2 8.9 ± 0.1 (1.4) 1.23 (1.04, 1.41) nd nd nd
15 CH2CH2OCH3 7.7 ± 0.2 (23) 0.70 (0.70, 0.70) (4.3 ± 0.8) × 10
5 (6.3 ± 0.7) × 10−4 27 ± 2.6
16 CH2CH2CH2OH 7.1 ± 0.1 (81) 1.04 ± 0.11 nd nd nd
17 CH2CH(CH3)2 8.9 ± 0.02 (1.2) 1.64 ± 0.24 (7.8 ± 2.7) × 10
5 (2.0 ± 0.8) × 10−4 148 ± 102
18 CH2C(CH3)3 8.5 ± 0.1 (3.5) 1.73 ± 0.28 (5.5 ± 1.3) × 10
5 (1.1 ± 0.4) × 10−4 250 ± 147
19 CH2CH2CH(CH3)2 8.5 ± 0.04 (3.5) 1.39 (1.23; 1.55) nd nd nd
20 CH2CH2C(CH3)3 8.1 ± 0.02 (8.0) 0.95 (1.02, 0.87) nd nd nd
21 CH2Si(CH3)3 8.6 ± 0.03 (2.7) 1.36 (1.26, 1.45) nd nd nd
2 CH2C3H5 9.0 ± 0.02 (1.0) 2.68 ± 0.48 (2.8 ± 0.5) × 10
6 (6.0 ± 1.7) × 10−5 315 ± 105
22 CH2C4H7 8.6 ± 0.03 (2.7) 1.48 (1.66, 1.30) nd nd nd
apKi ± SEM (n ≥ 3, average Ki value in nM), obtained at 25 °C from radioligand binding assays with [3H]34 on human adenosine A3 receptors
stably expressed on CHO cell membranes. bKRI ± SEM (n = 3) or KRI (n = 2, individual estimates in parentheses), obtained at 10 °C from dual-
point competition association assays with [3H]34 on human adenosine A3 receptors stably expressed on CHO cell membranes.
ckon ± SEM (n ≥ 3),
obtained at 10 °C from competition association assays with [3H]34 on human adenosine A3 receptors stably expressed on CHO cell membranes.
dkoff ± SEM (n ≥ 3), obtained at 10 °C from competition association assays with [3H]34 on human adenosine A3 receptors stably expressed on
CHO cell membranes. eRT (min) = 1/(60 × koff).
fnd = not determined.
Table 3. Binding Aﬃnities and Kinetic Parameters of Pyrido[2,1-f ]purine-2,4-dione Derivatives with Modiﬁcation at R2
compd R2 pKi
a ± SEM (mean Ki in nM) KRI
b kon
c (M−1 s−1) koff
d (s−1) RTe (min)
2 benzyl 9.0 ± 0.02 (1.0) 2.68 ± 0.48 (2.8 ± 0.5) × 106 (6.0 ± 1.7) × 10−5 315 ± 105
24 3-CH3-benzyl 8.8 ± 0.02 (1.5) 1.18 (1.18, 1.17) nd
f nd nd
25 4-CH3-benzyl 9.0 ± 0.1 (0.92) 1.15 (1.03, 1.27) nd nd nd
26 4-CH2CH3-benzyl 9.2 ± 0.04 (0.71) 0.81 (0.82, 0.79) nd nd nd
27 3-OCH3-benzyl 9.4 ± 0.03 (0.38) 2.24 (2.32, 2.15) (4.8 ± 0.2) × 10
5 (4.7 ± 0.7) × 10−5 376 ± 58
28 4-OCH3-benzyl 8.9 ± 0.01 (1.4) 1.39 (1.22, 1.55) (4.8 ± 0.1) × 10
5 (7.8 ± 2.0) × 10−5 250 ± 72
29 3-Cl-benzyl 8.3 ± 0.02 (4.9) 0.89 (1.06, 0.72) (8.2 ± 1.3) × 105 (4.7 ± 0.7) × 10−4 36 ± 5.5
30 4-Cl-benzyl 8.9 ± 0.01 (1.2) 1.11 (1.02, 1.20) (3.0 ± 0.3) × 106 (8.2 ± 0.2) × 10−4 20 ± 0.5
31 3,4-dichlorobenzyl 8.3 ± 0.01 (5.3) 3.12 (3.49, 2.75) (1.0 ± 0.1) × 105 (5.3 ± 1.5) × 10−5 391 ± 137
32 4-Br-benzyl 8.9 ± 0.1 (1.2) 1.19 (1.30, 1.08) nd nd nd
33 phenethyl 8.1 ± 0.04 (7.7) 1.09 (1.21, 0.97) nd nd nd
apKi ± SEM (n ≥ 3, average Ki value in nM), obtained at 25 °C from radioligand binding assays with [3H]34 on human adenosine A3 receptors
stably expressed on CHO cell membranes. bKRI ± SEM (n = 3) or KRI (n = 2, individual estimates in parentheses), obtained at 10 °C from dual-
point competition association assays with [3H]34 on human adenosine A3 receptors stably expressed on CHO cell membranes.
ckon ± SEM (n ≥ 3),
obtained at 10 °C from competition association assays with [3H]34 on human adenosine A3 receptors stably expressed on CHO cell membranes.
dkoff ± SEM (n ≥ 3), obtained at 10 °C from competition association assays with [3H]34 on human adenosine A3 receptors stably expressed on
CHO cell membranes. eRT (min) = 1/(60 × koff).
fn.d. = not determined.
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assay,27 allowing for the semiquantitative estimation of the
compounds’ dissociation rates and therefore the compounds’
RTs. The speciﬁc binding of [3H]34 was measured after 20 and
240 min in the absence and presence of a single concentration
(i.e., 1 × IC50) of unlabeled human adenosine A3 receptor
antagonists, which yielded their kinetic rate index (KRI). A long
RT compound shows a characteristic “overshoot” followed by a
steady decrease in speciﬁc binding until a new equilibrium is
reached; in such a case. the KRI value is greater than unity.
Conversely, a ligand with a fast dissociation rate is represented
by a more shallow curve, yielding a KRI value smaller than one
when dividing the binding at t1 by the binding at t2. The KRI
values in the series ranged from 0.38 to 4.06 (Table 1, 2, and
3).
Compounds with a KRI value less than 0.7 or greater than
1.5 were selected for complete kinetic characterization through
the use of a competition association assay with [3H]34 (Figure
1A). To obtain extensive structure−kinetics relationships
(SKRs), close structural analogues (9, 28, 29, and 30) of 1
were also tested to obtain their association (kon) and
dissociation (koff) rate constants. Association rate constants
varied by 30-fold, ranging from (1.0 ± 0.1) × 105 M−1 s−1 for
antagonist 31 to (3.0 ± 0.3) × 106 M−1 s−1 for antagonist 30
(Table 3). Interestingly, there was an approximately 290-fold
diﬀerence in dissociation rate constants, reﬂecting the divergent
KRI values. Antagonist 5 had the fastest dissociation rate
constant of (1.4 ± 0.5) × 10−2 s−1 and thus the shortest RT of
2.2 min, while both antagonist 27 and 31 had the slowest
Figure 1. (A) Representative competition association assay curves of [3H]34 in the absence (control) or presence of a long residence time
compound 27 and a short residence time compound 5. Experiments were performed at 10 °C using the compound’s respective IC50 value at the
hA3R. (B) Competition association curves of [
3H]34 in the absence (control) or presence of long residence time compound 27. Experiments were
performed at 25 °C using the compound’s respective IC50 value at the hA3R. t1 is the radioligand binding at 20 min, while t2 is the radioligand
binding at 240 min.
Figure 2. Correlations between the negative logarithm of the human adenosine A3 receptor antagonists’ dissociation rates (pkoff) and their kinetic
rate index (KRI) (A), the human adenosine A3 receptor antagonists’ aﬃnity (pKi) and their “kinetic KD” (pKD) (B), association rate constants (log
kon) (C), and dissociation rate constants (pkoff) (D). The central line corresponds to the linear regression of the data, the dotted lines represent the
95% conﬁdence intervals for the regression. Data used in these plots are detailed in Tables 1−3. Data are expressed as mean from at least three
independent experiments.
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dissociation rate constants of (4.7 ± 0.7) × 10−5 s−1 and (5.3 ±
1.5) × 10−5 s−1, respectively, and thus the longest RTs of 376
and 391 min, respectively. Notably, the long RT antagonist 27
(Figure 1A) displayed a typical “overshoot” in the competition
association curve, indicative of a slower dissociation than the
radiolabeled probe [3H]34, while the short RT antagonists,
exempliﬁed by antagonist 5 (Figure 1A), presented more
shallow, gradually ascending curves. There was a good
correlation between the negative logarithm of the antagonists’
dissociation rate constants and their KRI values derived from
the kinetic screen (Figure 2A), which conﬁrmed that a
compound’s KRI value is a good predictor for its dissociation
rate constant. Notably, the experimental temperatures in the
kinetic assays were lower than in the equilibrium displacement
assays (25 °C vs 10 °C) because kinetic studies performed at 25
°C were compromised by the nature of the compounds tested.
This is shown in Figure 1B, where the “overshoot” of long RT
antagonist 27 happened before the t1 checkpoint of 20 min,
Figure 3. 2-Cl-IB-MECA-stimulated [35S] GTPγS binding to hA3R stably expressed on CHO cell membranes (25 °C) in the absence or presence of
long-residence-time antagonist 27 (A and B, normalized and combined, n ≥ 3) or short-residence-time antagonist 5 (C and D, normalized and
combined, n ≥ 3). Antagonist 27 (A) and 5 (C) were incubated for 60 min prior to the challenge of the hA3R agonist 2-Cl-IB-MECA, at a
concentration ranging from 0.1 nM to 10 μM, for another 30 min. Antagonist 27 (B) and 5 (D) were coincubated with 2-Cl-IB-MECA, at the same
concentration range, for 30 min. The agonist curves were generated in the presence of increasing concentrations of antagonists, namely 30-, 100-,
and 300-fold their respective Ki values. Curves were ﬁtted to a four parameter logistic dose−response equation. Data is from at least three
independent experiments performed in duplicate, normalized according to the maximal response (100%) produced by 2-Cl-IB-MECA alone. The
shift in agonist EC50 values was determined to perform Schild analyses. Two-way ANOVA with Dunnett’s post-test was applied for the comparison
of Emax by agonist control, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, **** p < 0.0001, ns for not signiﬁcant.
Figure 4. Kinetic map (y axis, kon in M
−1 s−1; x axis, koff in s
−1) of all compounds that were kinetically characterized in this study. kon and koff values
were obtained through competition association assays performed at the hA3R. The kinetically derived aﬃnity (KD = koff/kon) is represented through
diagonal parallel lines. Group A: compounds that show similar koff values but due to diﬀering kon values have diﬀerent KD values. Group B:
compounds that display similar KD values despite showing divergent koff and kon values. Group C: compounds with similar kon values, but due to
diﬀering koff values have diﬀerent KD values.
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which did not happen at 10 °C. A signiﬁcant correlation was
also observed between the antagonist aﬃnities (Ki values)
determined in equilibrium displacement experiments and their
kinetic KD values derived from competition association
experiments (Figure 2B), despite the diﬀerences in assay
temperature (25 °C vs 10 °C). Interestingly, the kinetic
association rate constants (kon) did not show any signiﬁcant
correlation with aﬃnity (Figure 2C), while the dissociation rate
constants (koff) had a fair correlation with aﬃnity (Figure 2D).
The representative long RT and short RT antagonists (27
and 5) were selective for the hA3 receptor when compared to
other adenosine receptors (i.e., human adenosine A1 and A2A
receptor, Supporting Information, Table S1). These two
antagonists (27 and 5) with comparable association rate
constants but distinct dissociation rate constants (or RTs) were
further analyzed in a [35S]GTPγS binding assay in which we
studied the (in)surmountable antagonism induced by the two
compounds (Figure 3). Moreover, a kon−koff−KD “kinetic map”
(Figure 4) was constructed based on the compounds’ divergent
aﬃnities (expressed as kinetic KD values) and kinetics
parameters, yielding a division of these antagonists into three
diﬀerent subcategories: antagonists that show similar koff values
(<2-fold) but due to diﬀering kon values (>28-fold) have
diﬀerent KD values (∼100-fold, group A), antagonists that
display similar KD values (<10-fold) despite showing divergent
koff and kon values (17-fold and 30-fold, group B), and
antagonists with similar kon values (<5-fold) but due to
diﬀering koff values (∼290-fold) have diﬀerent KD values (>110-
fold, group C). Additionally, we applied molecular modeling to
compare the binding behavior in some molecular detail of
several antagonists with similar aﬃnities (2 vs 10; 31 vs 29 or
30) (Figure 5).
Structure−Aﬃnity Relationships (SAFIRs) and Struc-
ture−Kinetics Relationships (SKRs). According to previous
studies from our group,23,24 methoxy-substitution at the C8
position (Table 1) of the pyrido[2,1-f ]purine-2,4-dione scaﬀold
yielded selective hA3R antagonists with good aﬃnity (3.2 nM
for 1 as a reference compound). From our preliminary studies,
this methoxy-group appeared important for slow dissociation
(1 vs compound S2 from Supporting Information, Figure S1,
Table S2). Because of the nanomolar aﬃnity and close-to-unity
KRI value of 1, it was treated as the starting point of this SAFIR
and SKR study, having, on further analysis, an association rate
constant of (8.5 ± 1.2) × 105 M−1 s−1 and a dissociation rate
constant of (3.2 ± 0.02) × 10−4 s−1 (RT = 52 min). Next, we
decided to investigate R1 substitutions (Table 2), beginning
with antagonist 5 (R1 = H).
The Substitutions at R1 (Table 2). First, an increase in alkyl
chain length was investigated, indicating an elongated carbon
chain had a cumulative eﬀect on KRI (5, 6, 7, 8, 10, 11), with
the exception of antagonist 9 (KRI values from 0.38 to 4.06).
One could point to a possible correlation between lip-
ophilicities and dissociation rate constants (and consequently
RTs) to explain this trend (Supporting Information, Figure
S2A). However, with all of the antagonists kinetically
characterized, no such correlation was observed (Supporting
Information, Figure S2B). Therefore, other reasons should be
taken into account as to why elongating the carbon chain has
such a profound eﬀect on the ligand’s dissociation rate. The
role of membrane−drug interactions in determining the
pharmacological proﬁle is a possible reason, especially the
Figure 5. Docking of antagonist 2 into the binding site of the homology model of the adenosine A3 receptor based on the crystal structure of the
adenosine A2A receptor (PDB 4EIY).
41 Antagonist 2 is represented by black sticks, and residues within 5 Å of 2 are visualized as orange sticks. The
protein is represented by orange ribbons. Ligand and residues atoms color code: red = oxygen, blue = nitrogen, white = hydrogen. The overlay of
consecutively numbered hydration sites (colored spheres; for color code, see below) were calculated by WaterMap (left). Hydration sites shown as
red and orange spheres represent positions were “unstable” water molecules can be found, which should be displaced by antagonist 2. White spheres
symbolize “stable” water molecules, which are in exchange with the bulk solvent. Two diﬀerent binding modes are represented for antagonist 10
(cyan and gray sticks), which shows that the ﬂexible hexyl chain can displace diﬀerent hydration sites (8 for gray and 11 for cyan). For the key
hydration sites (8, 11, 22, 32, 37) surrounding the lipophilic “tails”, calculated ΔG values (in kcal/mol) with respect to bulk solvent are shown
(upper right). Hydration sites 6, 39, 42, and 45 are proposed to be displaced by the 3,4 dichloro substituents of 31; calculated ΔG values (in kcal/
mol) with respect to bulk solvent are shown (lower right).
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role long carbon tails have in such interactions.28 It is
interesting to point out that the aﬃnity of antagonist 11,
which had a traditional lead selection process taken place,
would most likely have resulted in the elimination of this
compound due to the more favorable aﬃnity and hydrophilic
properties of its shorter carbon chain counterparts (8 or 9)
(aﬃnities, 6.8 nM vs 1.5 nM or 3.5 nM; KRI values, 4.06 vs
1.29 or 1.11). This would have overlooked the eﬃcacy this
compound could oﬀer due to its longer residence time.
Second, the presence of a more rigid substitution of the R1
group of saturated equivalents (antagonists 1 and 8) led to
antagonists 12 and 14, with similar improvement in the aﬃnity
pairs (12 and 14, 5.9 and 1.4 nM; 1 and 8, 3.2 and 1.5 nM) and
KRI values (12 and 14, 0.72 and 1.23; 1 and 8, 0.99 and 1.29).
Further rigidiﬁcation with alkyne (13) rather than alkene (12)
maintained aﬃnities (4.3 vs 5.9 nM) and increased KRI values
(1.20 vs 0.72). This alkyne could be the starting point for a
further study on “click-chemistry” for introducing, e.g.,
ﬂuorescent tags.29−31
Third, the introduction of a polar atom or group in
antagonist 15 or 16, respectively, led to a decrease in aﬃnity
compared to their nonpolar counterpart 1 (23 or 81 nM vs 3.2
nM). The changes in KRI values between antagonist 1 and its
polar counterparts 15 and 16 can be considered minor (0.99 vs
0.70 and 1.04). Of note, by comparing aﬃnities and kinetic
proﬁles of polar antagonist 15 with its nonpolar equivalent 1,
we found the polarity at the “lipophilic carbon chain” resulted
in slower association (kon of (4.3 ± 0.8) × 10
5 M−1 s−1 vs (8.5
± 1.2) × 105 M−1 s−1) but faster dissociation (koff of (6.3 ± 0.7)
× 10−4 s−1 vs (3.2 ± 0.02) × 10−4 s−1), with a concomitant
decrease in aﬃnity (23 vs 3.2 nM).
Moreover, the bulkiness of the substituents was studied with
branched carbon side chains (17, 18, 19, 20, and 21) or
aliphatic rings (2 and 22). As to the branched carbon side
chains, compound aﬃnities remained in the nanomolar range,
while in terms of KRI values, 2-carbon-linker branched side
chains (17 and 18) caused larger KRI values than those of
either their linear counterparts (8 and 9) or 3-carbon-linear
branched side chains (19 and 20) (17, 1.64 vs 1.29 or 1.39; 18,
1.73 vs 1.11 or 0.95). Although the association rate constants of
17 and 18 were similar to other antagonists in Table 2, the
dissociation rate constants suggest their branched side chains
have an extra “anchoring” eﬀect compared with the linear
counterparts. For example, the koff of 18 with a 5-carbon
branched side chain was quite similar to 10 or 11, having a 6 or
7-carbon linear side chain ((1.1 ± 0.4) × 10−4 s−1 vs (8.2 ±
1.3) × 10−5 s−1 or (6.2 ± 0.2) × 10−5 s−1). The presence of a
slightly less polar but larger silicon atom (21) instead of carbon
(18) made the KRI value decrease (1.36 vs 1.73), although the
aﬃnity remained virtually the same (2.7 vs 3.5 nM).
Interestingly, another reported analogue (2)23 of compound
1, with cyclopropylmethyl substitution at the R1 group, led to
unique kinetic parameters, i.e., a combination of a fast
association rate constant ((2.8 ± 0.5) × 106 M−1 s−1 vs (8.5
± 1.2) × 105 M−1 s−1) and a slow dissociation rate constant
((6.0 ± 1.7) × 10−5 s−1 vs (3.2 ± 0.02) × 10−4 s−1), although
the aﬃnities of 2 and 1 were similar (1.0 ± 0.03 nM vs 3.2 ±
0.1 nM, respectively). The RT of compound 2 was the longest
in Table 2 with 315 min. For the antagonist with cyclo-
butylmethyl (22), aﬃnity (2.7 vs 1.0 nM) and KRI value (1.48
vs 2.68) were lower than for compound 2.
Although the dissociation rate constants of the antagonists in
Table 2 varied greatly depending on the R1 substituent, the
association rate constants were more similar (within 5-fold).
Association rate constants are often reasoned to be caused by a
diﬀusion limited process whereby the collision rate of ligand
and receptor determines the rate of ligand−receptor complex
formation.32 When no conformational changes are required for
the receptor and ligand to bind and when taking into account
the proportion of the receptor responsible for binding, this sets
the association rate constant at observed limits of around 107
M−1 s−1.33 As the association rate constants for all R1
substituted compounds were slower than the diﬀusion limit
by at least 3.5 fold (2), we hypothesize target engagement for
R1 substituted antagonists is more hampered than imposed by
the diﬀusion limit.
The Substitutions at R2 Group (Table 3). From Table 2, we
learned that cyclopropylmethyl-substituted antagonist 2 ex-
hibited a kinetic proﬁle as a long RT compound while showing
the aﬃnity previously reported.23 As a result, this compound
became the starting point for our exploration of the
substitutions (R2 group) on the aromatic ring.
Introduction of a nonpolar alkyl substituent on antagonist 2’s
benzyl ring (24, 25, 26), resulted in a decrease in KRI values
(from 2.68 to 0.81), while slight variations in aﬃnity were
observed.
Then, introduction of a polar methoxy substituent on
antagonist 2’s benzyl ring led to mixed results with a small
decrease in RT at para-position and a slight increase in RT at
meta-position in 28 (250 vs 315 min) and 27 (376 vs 315 min),
respectively. In particular, the long residence time for 27 in
combination with its subnanomolar aﬃnity (0.38 nM) made
this compound stand out in the series.
Next, halogen substitutions on antagonist 2’s benzyl ring
were examined. Apparently, the position of halogen substitution
is important for aﬃnity as para-substitution in antagonist 30
and 32 yielded similar aﬃnity compared to 2 (1.2 vs 1.2 vs 1.0
nM). The one compound with meta-substitution, 29, showed a
5-fold decrease in aﬃnity compared to 2 (4.9 vs 1.0 nM).
Dichloro-substituted compound 31 had the largest KRI value
(3.12) among the halogen-substituted antagonists; the para-
bromo substituted compound 32 was similar in this respect to
para-chloro substituted 30 (1.19 vs 1.11). In a full competition
association experiment, we determined the rate constants for
31 and learned it had the longest RT of all compounds
kinetically characterized (391 min), concomitant with the
slowest association rate constant of the compounds kinetically
characterized ((1.0 ± 0.1) × 105 M−1 s−1). Previous theoretical
studies have indicated the strength of halogen bonding can be
increased through the introduction of electron withdrawing
groups onto halobenzenes.34 Such would be the case for 31,
where the additional chloro substituent forms a stronger
halogen bonding interaction with the R2 binding pocket.
Introducing a phenethyl (33) rather than benzyl substituent
(2) led to a decrease in aﬃnity (7.7 vs 1.0 nM), while the KRI
value was also strongly aﬀected (1.09 vs 2.68). This observation
parallels our previous ﬁndings that the binding pocket for the
R2 substituent is of limited size.
23
Functional Assay. Following kinetic characterization, a
long (27) and a short (5) RT compound were chosen for
functional characterization in a [35S]GTPγS binding assay, also
because for these two compounds the kon values were similar
(4.8 ± 0.2) × 105 M−1 s−1 vs (5.3 ± 1.5) × 105 M−1 s−1). This
diﬀerence allowed a possible link to be made between RTs and
eﬃcacies. Pretreatment of hA3 receptor membranes with
increasing concentrations of the long RT antagonist 27, before
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stimulation by the A3 receptor agonist 2-Cl-IB-MECA, induced
insurmountable antagonism. In other words, the 2-Cl-IB-
MECA concentration−eﬀect curves were shifted to the right
with a concomitant decrease in the maximal response (Figure
3A). Conversely, the short RT antagonist 5 displayed
surmountable antagonism, shifting 2-Cl-IB-MECA’s curves to
the right without aﬀecting its maximum eﬀect (Figure 3B). In
this experimental setup, the Schild-slope of 5 generated from
Schild-plots was close to unity (Table 4), and the compound’s
pA2 value was comparable with its pKi value (6.8 ± 0.4 vs 7.0 ±
0.02). We also performed coincubation experiments with these
antagonists in the presence of 2-Cl-IB-MECA. In this
experimental setup, all antagonists produced a rightward shift
of the 2-Cl-IB-MECA concentration−eﬀect curves without a
suppression of the maximal response (Figure 3C,D). Notably,
the Schild-slopes of both long and short RT antagonists (27
and 5) were close to unity (0.9 ± 0.2 for 27, 1.0 ± 0.2 for 5,
Table 4). In addition, the pA2 value of 5 was comparable with
the result from the preincubation condition (7.2 ± 0.4 vs 6.8 ±
0.4, Table 4), and the pA2 value of 27 was also in agreement
with its pKi value (8.9 ± 0.3 vs 9.4 ± 0.03).
Kinetic Map. Using the association (kon) and dissociation
(koff) rate constants obtained from competition association
experiments (Tables 1−3), a kinetic map (Figure 4) was
constructed by plotting these values on the y-axis and x-axis,
respectively. The dashed diagonal parallel lines represent the
kinetically derived KD values (KD = koff/kon). Out of this map,
three subgroups emerged. Group A represents compounds that
exhibit similar koff values but with vastly diﬀerent kon values. As
a consequence, a diverse range of KD values was observed.
Previous SKR studies have primarily focused on optimizing
dissociation rates and RTs for predicting in vivo eﬃcacy and
creating a kinetically favorable ligand. Yet recently, there has
been greater acknowledgment of the important role that the
association rate constants may play in determining the eﬃcacy
of a drug as the result of increased rebinding or increased
drug−target selectivity.19 A kinetic map would thus allow for
the selection of compounds with appropriate RTs while
exploring the role of association rate constants in determining
eﬃcacy by choosing a rapidly or slowly associating compound,
i.e., 2 or 31 ((2.8 ± 0.5) × 106 M−1 s−1 vs (1.0 ± 0.1) × 105
M−1 s−1). Group B displays ligands that exhibit a narrow range
of aﬃnity (KD: 0.1−1 nM) yet a wide range of koff values that
result in RTs ranging from 20 to 391 min. This information
would have gone unnoticed in a traditional SAFIR hit-to-lead
approach and would most likely have led to the selection of
high aﬃnity compounds not in possession of a potentially
eﬃcacy promoting long residence time. Thus, combining
SAFIR with SKR aspects in lead optimization would allow the
selection of not only potent but also long RT compounds
through the drug development pipeline. Lastly, group C
represents compounds that present similar kon values but due to
diﬀering koff values show considerable diﬀerences in aﬃnities
(KD). This illustrates the diﬀerences that were observed in the
binding kinetics of the R1 and R2 substituents, as group C
mainly consists of R1 substituents (noncyclopropylmethyl
substituents), while group A mainly consists of R2 substituents
(cyclopropylmethyl substituents). This diﬀerence also suggests
a diﬀerent mode of receptor−ligand interaction during the
binding process of the two ligand groups.
Altogether, the construction of a kinetic map allows for a
more detailed categorization of compounds’ aﬃnities as
dictated by their kinetic rate constants. In previous studies,
such a separation has explained the diﬀerent therapeutic eﬀects
molecules exhibit highlighting the beneﬁts of such an in-depth
analysis.35,36
Given the putative link between RT and clinical eﬃcacy, it
may be postulated that the lack of hA3R antagonists progressing
from preclinical trials is due to insuﬃcient selection criteria
employed in these initial phases of hA3R drug screening. As
previously reported, hA3R antagonists are reasoned to be
beneﬁcial in the treatment of chronic obstructive pulmonary
disease (COPD).37 For this indication, a number of antagonists
are available that act at the muscarinic M3 receptor.
38 For these
therapeutics, their dosing regime and thus duration of action
have been linked to their RT. For example, aclidinium, which
requires a twice daily dosing regimen, exhibits a much shorter
RT than tiotropium that in turn requires only once daily
Table 4. Functional Activity of hA3 Receptor Antagonists from [
35S]GTPγS Binding Assays
aRTs were obtained from Tables 1 and 2. bObtained from Schild analyses. cN.A.: not applicable.
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dosing.16 This extended duration of action that enables long-
lasting eﬃcacy and practical dosing regimens at the muscarinic
M3 receptor is thought to be a beneﬁcial feature in the
treatment of chronic illnesses.39,40 As hA3R antagonists can be
used to treat chronic COPD but also a number of other chronic
disorders, we could imagine that considering the ligand’s kinetic
proﬁle early in the drug screening process would reduce the
likelihood of failure due to insuﬃcient eﬃcacy in future clinical
trials. Perhaps when selecting hA3R antagonists with a favorable
long RT, i.e., group A in the kinetic map, will we see the
therapeutic potential of the hA3R fulﬁlled.
Computational Studies. Finally, we decided to further
investigate the ligand−receptor interactions using a homology
model of the adenosine A3 receptor, based on the crystal
structure of the adenosine A2A receptor (PDB 4EIY).
41
WaterMap calculations were applied to try and explain the
variance in kinetic proﬁles of diﬀerent ligands by unfavorable
hydration.42,43
Antagonist 2 (in black stick representation) was docked in
the homology model. As a ﬁrst step, it was placed inside the
transmembrane bundle, with the tricyclic ring system
surrounded by TM3, TM6, and EL2. Hydrogen bonding was
constrained between the amide-hydrogen (−NH2, δ+) from
Asn2506.55 and the carbonyl-oxygen (−CO, δ−) at the C4-
position of the pyrido[2,1-f ]purine-2,4-dione scaﬀold (Figure
5, left). To compare diﬀerences between the ligands, an “apo”
WaterMap of the hA3 receptor was generated. Hydration sites
shown as red and orange spheres represent positions where
“unstable” water molecules are found. Antagonist 10 (hexyl-
substitution), with comparable koff ((8.2 ± 1.3) × 10
−5 s−1 vs
(6.0 ± 1.7) × 10−5 s−1) to 2 but 10-fold slower kon ((2.3 ± 1.0)
× 105 M−1 s−1 vs (2.8 ± 0.5) × 106 M−1 s−1), was docked with
two diﬀerent binding modes in the same binding site (Figure 5
upper right, cyan and gray sticks). We found additional unstable
waters (8, 11, 22 in Figure 5 upper right) surrounding the
lipophilic substituents of the compounds, which could be
explained as hindrance when the antagonist is associating with
the binding site.
The same WaterMap was used to investigate the kinetic
proﬁle of antagonist 31. Indeed, hydration sites 6, 39, 42, and
45 are proposed to be displaced by the 3,4-dichloro substituent.
Thus, both the association and dissociation of 31 were slowed
down by these unstable waters. For the association process, the
lipophilic 3,4-dichloro moiety has diﬃculty in approaching the
occupied unstable hydration sites ((1.0 ± 0.1) × 105 M−1 s−1,
slowest kon in the whole series); the same lipophilic 3,4-
dichloro substituent seems to provide more stabilization to the
receptor−ligand complex, thus hampering the dissociation
process ((5.3 ± 1.5) × 10−5 s−1, slowest koff in the whole
series). Interestingly, by removing a single chloro atom at either
the 3- or 4- position on the benzyl-ring (30 or 29), association
and dissociation rate constants became faster by approximately
10-fold. Although the diﬀerences in their kon and koff values
were modest (2−3 fold), the unstable hydration sites may
prevent the 4-chloro-substituted antagonist 30 from reaching
the hydration sites 6, 39, and 42 that interact with the 3-Cl
substituent; consequently, both its association and dissociation
rate constants were faster than of the 3-chloro-substituted
counterpart 29 (kon, (3.0 ± 0.3) × 10
6 M−1 s−1 vs (8.2 ± 1.3) ×
105 M−1 s−1; koff, (8.2 ± 0.2) × 10
−4 s−1 vs (4.7 ± 0.7) × 10−4
s−1).
■ CONCLUSIONS
We have demonstrated that, next to aﬃnity, additional
knowledge of target binding kinetics is useful for selecting
and developing new hA3R antagonists in the early phase of drug
discovery. By introducing proper substituents at the N3 position
or the N1 benzyl ring of a series of pyridopurinediones,
divergences in kinetic proﬁles were observed, while almost all
compounds had high and often similar aﬃnity. Two
representative ligands (5 and 27) were tested in [35S]GTPγS
binding assays, conﬁrming the link between their RTs and their
(in)surmountable antagonism. According to these ﬁndings, a
kon−koff−KD kinetic map was constructed and subsequently the
antagonists were divided into three subgroups. Additionally, we
also performed a computational modeling study that sheds light
on the crucial interactions (including with water molecules) for
both the association and dissociation kinetics of this family of
antagonists. It should be mentioned that the kinetic parameters
were derived at the hA3R, which may be diﬀerent in, e.g.,
rodents used in advanced animal models. Still, this study
suggests that favorable long RTs would be a proper indicator in
the development of hA3R antagonists for chronic inﬂammatory
conditions, e.g., COPD.
■ EXPERIMENTAL SECTION
Chemistry. All solvents and reagents were purchased from
commercial sources and were of analytical grade. Distilled water will
be referred to as H2O. TLC analysis was performed to monitor the
reactions, using Merck silica gel F254 plates. Grace Davison Davisil
silica column material (LC60A, 30−200 μm) was used to perform
column chromatography. Microwave reactions were performed in an
Emrys Optimizer (Biotage AB, formerly Personal Chemistry). 1H and
13C NMR spectra were recorded on a Bruker DMX-400 (400 MHz)
spectrometer, using tetramethylsilane as internal standard. Chemical
shifts are reported in δ (ppm) and the following abbreviations are
used: s, singlet; d, doublet; dd, double doublet; t, triplet; m, multiplet.
The analytical purity of the ﬁnal compounds is 95% or higher and was
determined by high-performance liquid chromatography (HPLC) with
a Phenomenex Gemini 3 μm C18 110A column (50 mm × 4.6 mm, 3
μm), measuring UV absorbance at 254 nm. The sample preparation
and HPLC method was as follows: 0.3−0.6 mg of compound was
dissolved in 1 mL of a 1:1:1 mixture of CH3CN/H2O/t-BuOH and
eluted from the column within 15 min at a ﬂow rate of 1.3 mL/min.
The elution method was set up as follows: 1−4 min isocratic system of
H2O/CH3CN/1% TFA in H2O, 80:10:10; from the fourth min, a
gradient was applied from 80:10:10 to 0:90:10 within 9 min, followed
by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. Liquid
chromatography−mass spectrometry (LC−MS) analyses were per-
formed using a Thermo Finnigan SurveyorLCQ Advantage Max
LC−MS system and a Gemini C18 Phenomenex column (50 mm ×
4.6 mm, 3 μm). The elution method was set up as follows: 1−4 min
isocratic system of H2O/CH3CN/1% TFA in H2O, 80:10:10; from the
fourth min, a gradient was applied from 80:10:10 to 0:90:10 within 9
min, followed by 1 min of equilibration at 0:90:10 and 1 min at
80:10:10.
1-Benzyl-8-methoxy-1H,3H-pyrido[2,1-f ]purine-2,4-dione (5).24
6-Amino-1-benzyluracil (4)25 (10.8 g, 49.7 mmol, 1.00 equiv) was
suspended in CH3CN (370 mL). N-Bromosuccinimide (17.7 g, 99.4
mmol, 2.00 equiv) was added to the suspension, and the mixture was
heated at 80 °C for 1 h, after which full conversion was shown by TLC
(1:9 CH3OH/CH2Cl2 + 3% triethylamine). Subsequently, 4-
methoxypyridine (15.1 mL, 149.2 mL, 3.00 equiv) was added and
the mixture was heated at 80 °C during 10 h. Full consumption of the
bromo intermediate was shown by TLC (1% CH3OH/CH2Cl2). A
precipitate was formed overnight at RT, which was collected by
ﬁltration and washed with diethyl ether. This yielded the desired
compound as a white solid (10.2 g, 31.6 mmol, 64%). 1H NMR (400
MHz, DMSO-d6) δ: 11.11 (s br, 1H), 8.72 (d, J = 7.2 Hz, 1H), 7.39−
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7.29 (m, 4H), 7.28−7.22 (m, 2H), 6.91 (dd, J = 7.2, 2.0 Hz, 1H), 5.19
(s, 2H), 3.89 (s, 3H) ppm. NMR was according to literature data.24
General Procedure for the Preparation of N3-Substituted 1-
Benzyl-8-methoxy-1H,3H-pyrido[2,1-f ]purine-2,4-diones (1, 2,
6−22).24 The compounds were synthesized using the procedure
described by Priego et al.,24 but 5 equiv of the alkyl halide was used
instead of 1.5 equiv and the reaction mixture was heated to 80 °C
overnight in all cases. The pure compounds were obtained by silica
column chromatography using a mixture of petroleum ether/ethyl
acetate (2:1) as eluent, if not otherwise stated.
1-Benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f ]purine-2,4-
dione (1).24 The pure product was obtained by column chromatog-
raphy using petroleum ether/ethyl acetate (1:1) as eluent, yielding a
white solid 113 mg, 0.31 mmol, 60%. 1H NMR (400 MHz, CDCl3) δ:
8.83 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 2H), 7.34−7.25 (m, 3H),
6.98 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.6, 2.8 Hz, 1H), 5.37 (s, 2H),
4.02 (t, J = 7.6 Hz, 2H), 3.92 (s, 3H), 1.74 (sextet, J = 7.6 Hz, 2H),
0.99 (t, J = 7.6 Hz, 3H) ppm.24 MS [ESI + H]+: calcd for C20H20N4O3,
364.15; found, 365.0.
1-Benzyl-3-(cyclopropylmethyl)-8-methoxypyrido[2,1-f ]purine-
2,4(1H,3H)-dione (2).23 The pure product was obtained by column
chromatography using a mixture of 2% CH3OH/CH2Cl2 as eluent,
yielding a white solid, 1.51 g, 3.98 mmol, 86%. 1H NMR (400 MHz,
CDCl3) δ: 8.82 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 2H), 7.33−
7.23 (m, 3H), 6.97 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 8.4, 2.4 Hz, 1H),
5.37 (s, 2H), 3.94 (d, J = 7.4 Hz, 2H), 3.92 (s, 3H), 1.35−1.25 (m,
1H), 0.47−0.44 (m, 4H) ppm. MS [ESI + H]+: calcd for C21H20N4O3,
376.15; found, 376.9.
1-Benzyl-8-methoxy-3-methylpyrido[2,1-f ]purine-2,4(1H,3H)-
dione (6). Reaction was performed in a sealed tube, and 50 equiv of
methyl iodide was used. The residue was puriﬁed by silica column
chromatography eluting with a petroleum ether/ethyl acetate (1:1)
mixture, yielding a white solid, 25 mg, 0.074 mmol, 15%. 1H NMR
(400 MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.2 Hz,
2H), 7.33−7.24 (m, 3H), 6.99 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.6,
2.4 Hz, 1H), 5.37 (s, 2H), 3.93 (s, 3H), 3.45 (s, 3H) ppm. MS [ESI +
H]+: calcd for C18H16N4O3, 336.12; found, 337.2.
1-Benzyl-3-ethyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-dione
(7). The pure product was obtained by column chromatography using
petroleum ether/ethyl acetate (1:1) as eluent, yielding a white solid, 58
mg, 0.17 mmol, 33%. 1H NMR (400 MHz, CDCl3) δ: 8.83 (d, J = 7.2
Hz, 1H), 7.54 (d, J = 7.2 Hz, 2H), 7.33−7.24 (m, 3H), 6.98 (d, J = 2.0
Hz, 1H), 6.74 (dd, J = 7.6, 2.8 Hz, 1H), 5.36 (s, 2H), 4.12 (q, J = 7.2
Hz, 2H), 3.92 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H) ppm. MS [ESI + H]+:
calcd for C19H18N4O3, 350.14; found, 351.0.
1-Benzyl-3-butyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-dione
(8). Puriﬁed by column chromatography using petroleum ether/EtOAc
(3:1), yielding a white solid 10 mg, 0.026 mmol, 5%. 1H NMR (400
MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 6.8 Hz, 2H),
7.24−7.33 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.4, 2.6 Hz,
1H), 5.36 (s, 2H), 4.04 (t, J = 7.6 Hz, 2H), 3.93 (s, 3H), 1.70−1.64
(m, 2H), 1.40 (sextet, J = 3.6 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H) ppm.
MS [ESI + H]+: calcd for C21H22N4O3, 378.17; found, 378.9.
1-Benzyl-8-methoxy-3-pentyl-1H,3H-pyrido[2,1-f ]purine-2,4-
dione (9). White solid, 110 mg, 0.28 mmol, yield 56%. 1H NMR (400
MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 7.2 Hz, 2H),
7.34−7.25 (m, 3H), 6.97 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.6, 2.8 Hz,
1H), 5.37 (s, 2H), 4.05 (t, J = 7.6 Hz, 2H), 3.93 (s, 3H), 1.72−1.66
(m, 2H), 1.39−1.37 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS [ESI +
H]+: calcd for C22H24N4O3, 392.18; found, 393.1.
1-Benzyl-3-hexyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-
dione (10). White solid, 90 mg, 0.22 mmol, yield 44%. 1H NMR (400
MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 6.8 Hz, 2H),
7.34−7.25 (m, 3H), 6.98 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.6, 2.4 Hz,
1H), 5.37 (s, 2H), 4.05 (t, J = 7.6 Hz, 2H), 3.92 (s, 3H), 1.69 (pentet,
J = 7.6 Hz, 2H), 1.40−1.26 (m, 6H), 0.89 (t, J = 7.2 Hz, 3H) ppm. MS
[ESI + H]+: calcd for C23H26N4O3, 406.20; found, 407.1.
1-Benzyl-3-heptyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-
dione (11). Column chromatography using a mixture of petroleum
ether/ethyl acetate (3:1) as eluent yielded 131 mg of the pure product
as white solid, 0.31 mmol, 62%. 1H NMR (400 MHz, CDCl3)
1H
NMR (400 MHz, CDCl3) δ: 8.80 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 6.8
Hz, 2H), 7.32−7.25 (m, 3H), 6.95 (d, J = 2.4 Hz, 1H), 6.71 (dd, J =
7.2, 2.4 Hz, 1H), 5.35 (s, 2H), 4.03 (t, J = 7.6, 2H), 3.90 (s, 3H), 1.67
(pentet, J = 7.6 Hz, 2H), 1.38−1.26 (m, 8H), 0.87 (t, J = 7.2 Hz, 3H)
ppm. MS [ESI + H]+: calcd for C24H48N4O3, 420.22; found, 421.2.
3-Allyl-1-benzyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-dione
(12). Puriﬁed by column chromatography using petroleum ether/ethyl
acetate (1:1) as eluent, yielding a white solid, 73 mg, 0.20 mmol, 40%.
1H NMR (400 MHz, CDCl3) δ: 8.82 (d, J = 7.6 Hz, 1H), 7.55 (d, J =
7.2 Hz, 2H), 7.34−7.25 (m, 3H), 6.99 (d, J = 2.0 Hz, 1H), 6.75 (dd, J
= 7.6, 2.4 Hz, 1H), 6.02−5.92 (m, 1H), 5.38 (s, 2H), 5.29 (dd, J =
17.2, 1.2 Hz, 1H), 5.20 (d, J = 10.0 Hz, 1H), 4.68 (d, J = 5.6 Hz, 2H),
3.93 (s, 3H) ppm. MS [ESI + H]+: calcd for C20H18N4O3, 362.14;
found, 363.0.
1-Benzyl-8-methoxy-3-(prop-2-yn-1-yl)pyrido[2,1-f ]purine-2,4-
(1H,3H)-dione (13). The pure product was obtained by column
chromatography using petroleum ether/ethyl acetate (1:1) as eluent,
yielding a white solid, 60 mg, 0.17 mmol, 3%. 1H NMR (400 MHz,
CDCl3) δ: 8.82 (d, J = 7.2 Hz, 1H), 7.57 (d, J = 6.8 Hz, 2H), 7.36−
7.26 (m, 3H), 6.99 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 7.2, 2.4 Hz, 1H),
5.38 (s, 2H), 4.83 (d, J = 2.4 Hz, 2H), 3.94 (s, 3H), 2.19 (t, J = 2.4 Hz,
1H) ppm. MS [ESI + H]+: calcd for C20H16N4O3, 360.12; found,
361.1.
1-Benzyl-3-(but-3-en-1-yl)-8-methoxypyrido[2,1-f ]purine-2,4-
(1H,3H)-dione (14). White solid, 18 mg, 0.05 mmol, yield 10%. 1H
NMR (400 MHz, CDCl3) δ: 8.84 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.2
Hz, 2H), 7.35−7.28 (m, 3H), 7.00 (d, J = 2.4 Hz, 1H), 6.77 (dd, J =
7.6, 2.4 Hz, 1H), 5.91−5.84 (m, 1H), 5.39 (s, 2H), 5.08 (dd, J = 16.8,
1.2 Hz, 1H), 5.02 (d, J = 10.4, 1H), 4.15 (t, J = 7.2 Hz, 2H), 3.95 (s,
3H), 2.48 (q, J = 7.2 Hz, 2H) ppm. MS [ESI + H]+: calcd for
C21H20N4O3, 376.15; found, 376.9.
1-Benzyl-8-methoxy-3-(2-methoxyethyl)-1H,3H-pyrido[2,1-f ]-
purine-2,4-dione (15). Puriﬁed by column chromatography using a
mixture of 2% CH3OH in CH2Cl2 yielded the product as a white solid,
70 mg, 0.18 mmol, 37%. 1H NMR (400 MHz, CDCl3) δ: 8.83 (d, J =
7.2 Hz, 1H), 7.54 (d, J = 6.8 Hz, 2H), 7.33−7.24 (m, 3H), 6.98 (d, J =
2.4 Hz, 1H), 6.74 (dd, J = 7.6, 2.4 Hz, 1H), 5.36 (s, 2H), 4.30 (t, J =
6.0 Hz, 2H), 3.93 (s, 3H), 3.68 (t, J = 6.0 Hz, 2H), 3.36 (s, 3H) ppm.
MS [ESI + H]+: calcd for C20H20N4O3, 380.15; found, 380.8.
1-Benzyl-3-(3-hydroxypropyl)-8-methoxypyrido[2,1-f ]purine-2,4-
(1H,3H)-dione (16). Puriﬁed by column chromatography using a
mixture of petroleum ether/EtOAc (1:2), followed by recrystallization
from CH3OH/EtOAc. Yield: white solid, 106 mg, 0.28 mmol, 28%.
1H
NMR (400 MHz, CDCl3) δ: 8.80 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 7.6
Hz, 2H), 7.33−7.24 (m, 3H), 6.99 (d, J = 2.4 Hz, 1H), 6.76 (dd, J =
7.6, 2.4 Hz, 1H), 5.37 (s, 2H), 4.22 (t, J = 6.0 Hz, 2H), 3.93 (s, 3H),
3.53 (t, J = 5.6 Hz, 2H), 1.92 (pentet, J = 5.6 Hz, 2H) ppm. MS [ESI +
H]+: calcd for C20H20N4O3, 380.15; found, 380.9.
1-Benzyl-3-isobutyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-
dione (17). White solid, 0.08 mmol, 29 mg, yield 15%. 1H NMR (400
MHz, CDCl3) δ: 8.86 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 7.2 Hz, 2H),
7.33−7.28 (m, 3H), 7.00 (d, J = 2.0 Hz, 1H), 6.76 (dd, J = 7.6, 2.4 Hz,
1H), 5.39 (s, 2H), 3.95 (s, 3H), 3.92 (d, J = 7.6 Hz, 2H), 2.22 (nonet,
J = 7.2 Hz, 1H), 0.97 (d, J = 6.8 Hz, 6H) ppm. MS [ESI + H]+: calcd
for C21H22N4O3, 378.17; found, 379.0.
1-Benzyl-8-methoxy-3-(3-neopentyl)-1H,3H-pyrido[2,1-f ]purine-
2,4-dione (18). Puriﬁed by column chromatography using a mixture of
1% CH3OH in CH2Cl2 as eluent, yielding the product as a white solid,
0.025 mmol, 20 mg, 5%. 1H NMR (400 MHz, CDCl3) δ: 8.84 (d, J =
7.2 Hz, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.32−7.25 (m, 3H), 6.98 (d, J =
2.4 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 5.37 (s, 2H), 3.99 (s, 2H),
3.92 (s, 3H), 0.98 (s, 9H) ppm. MS [ESI + H]+: calcd for
C22H24N4O3, 392.18; found, 393.0.
1-Benzyl-3-isopentyl-8-methoxypyrido[2,1-f ]purine-2,4(1H,3H)-
dione (19). Yield: white solid, 104 mg, 0.26 mmol, 53%. 1H NMR
(400 MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 7.2 Hz,
2H), 7.33−7.24 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.6,
2.4 Hz, 1H), 5.36 (s, 2H), 4.08−4.04 (m, 2H), 3.93 (s, 3H), 1.69
(nonet, J = 6.8 Hz, 1H), 1.59−1.53 (m, 2H), 0.98 (d, J = 6.4 Hz, 6H)
ppm. MS [ESI + H]+: calcd for C22H24N4O3, 392.18; found, 393.1.
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1-Benzyl-3-(3,3-dimethylbutyl)-8-methoxy-pyrido[2,1-f ]purine-
2,4(1H,3H)-dione (20). Yield: white solid, 81 mg, 0.20 mmol, 40%.
1NMR (400 MHz, CDCl3) δ: 8.84 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 7.2,
2H), 7.35−7.27 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.2,
2.4 Hz, 1H), 5.38 (s, 2H), 4.12−4.08 (m, 2H), 3.93 (s, 3H), 1.61−1.57
(m, 2H), 1.04 (s, 9H) ppm. MS [ESI + H]+: calcd for C23H26N4O3,
406.20; found, 407.1.
1-Benzyl-8-methoxy-3-((trimethylsilyl)methyl)pyrido[2,1-f ]-
purine-2,4(1H,3H)-dione (21). White solid, 137 mg, 0.34 mmol, yield
67%. 1H NMR (400 MHz, CDCl3) δ: 8.84 (d, J = 7.2 Hz, 1H), 7.50
(d, J = 6.8 Hz, 2H), 7.32−7.24 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.73
(d, J = 7.2, 2.4 Hz, 1H), 5.39 (s, 2H), 3.93 (s, 3H), 3.64 (s, 2H), 0.08
(s, 9H) ppm. MS [ESI + H]+: calcd for C21H24N4O3Si, 408.16; found,
409.2.
1-Benzyl-3-(cyclobutylmethyl)-8-methoxypyrido[2,1-f ]purine-
2,4(1H,3H)-dione (22). White solid, 90 mg, 0.23 mmol, yield 46%. 1H
NMR (400 MHz, CDCl3) δ: 8.82 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 7.2
Hz, 2H), 7.33−7.13 (m, 3H), 6.69 (d, J = 1.8 Hz, 1H), 6.73 (dd, J =
7.2, 2.4 Hz, 1H), 5.35 (s, 2H), 4.11 (d, J = 7.6 Hz, 2H), 3.92 (s, 3H),
2.83−2.72 (m, 1H), 2.05−1.95 (m, 2H), 1.90−1.79 (m, 4H) ppm. MS
[ESI + H]+: calcd for C22H22N4O3, 390.17; found, 391.2.
3-(Cyclopropylmethyl)-8-methoxypyrido[2,1-f ]purine-2,4-
(1H,3H)-dione (23).23 Prepared following a slightly modiﬁed
procedure described by Priego et al. In total, four portions of 8
equiv of ammonium formate (after 0, 2, 4, and 6 h) and three portions
of 0.15 equiv of 20% Pd(OH)2 (0, 4, and 6 h) were added, after which
full conversion was reached after overnight reﬂux visualized by TLC
(3% CH3OH/CH2Cl2). The reaction mixture was ﬁltered over Celite
and the residue extracted 5 times with hot DMF. The combined
organic layer was concentrated in vacuo, which resulted in a
quantitative yield. 1H NMR in accordance to data in literature.23
General Procedure for the Preparation of N1-Substituted-3-
cyclopropylmethyl-8-methoxy-1H,3H-pyrido[2,1-f ]purine-2,4-
diones (24−33).23 The compounds were synthesized according to
the procedure described by Priego et al.2 Puriﬁcation by silica column
chromatography using an eluent mixture of petroleum ether/ethyl
acetate (3:1) yielded the pure ﬁnal products.
3-(Cyclopropylmethyl)-8-methoxy-1-(3-methylbenzyl)pyrido[2,1-
f ]purine-2,4(1H,3H)-dione (24). White solid, 79 mg, 0.20 mmol, yield
57%. 1H NMR (400 MHz, CDCl3) δ: 8.84 (d, J = 7.2 Hz, 1H), 7.36 (s,
2H), 7.22 (t, J = 7.6 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 2.4
Hz, 1H), 6.75 (dd, J = 7.2, 2.4 Hz, 1H), 5.36 (s, 2H), 3.97 (d, J = 7.2
Hz, 2H), 3.94 (s, 3H), 2.34 (s, 3H), 1.37−1.31 (m, 1H), 0.52−0.45
(m, 4H) ppm. MS [ESI + H]+: calcd for C22H22N4O3, 390.17; found,
391.0.
3-(Cyclopropylmethyl)-8-methoxy-1-(4-methylbenzyl)pyrido[2,1-
f ]purine-2,4(1H,3H)-dione (25). See ref 23.
3-(Cyclopropylmethyl)-1-(4-ethylbenzyl)-8-methoxypyrido[2,1-f ]-
purine-2,4(1H,3H)-dione (26). White solid, 43 mg, 0.11 mmol, yield
21%. 1H NMR (400 MHz, CDCl3) δ: 8.82 (d, J = 7.6 Hz, 1H), 7.48
(d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 2.0 Hz, 1H),
6.73 (dd, J = 7.2, 2.4 Hz, 1H), 5.34 (s, 2H), 3.95−3.93 (m, 5H), 2.60
(q, J = 7.6 Hz, 2H), 1.34−1.28 (m, 1H), 1.19 (t, J = 7.6 Hz, 3H),
0.50−0.42 (m, 4H) ppm. MS [ESI + H]+: calcd for C23H24N4O3,
404.18; found, 405.2.
3-(Cyclopropylmethyl)-8-methoxy-1-(3-methoxybenzyl)pyrido-
[2,1-f ]purine-2,4(1H,3H)-dione (27). White solid, 20 mg, 0.049 mmol,
yield 14%. 1H NMR (400 MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H),
7.23 (t, J = 8.0 Hz, 1H), 7.15−7.10 (m, 2H), 6.97 (d, J = 1.6 Hz, 1H),
6.80 (dd, J = 8.4, 2.4 Hz, 1H), 6.74 (dd, J = 7.6, 2.4 Hz, 1H), 5.35 (s,
2H), 3.96−3.92 (m, 5H), 3.77 (s, 3H), 1.35−1.28 (m, 1H), 0.50−0.45
(m, 4H) ppm. MS [ESI + H]+: calcd for C22H22N4O4, 406.16; found,
406.9.
3-(Cyclopropylmethyl)-8-methoxy-1-(4-methoxybenzyl)pyrido-
[2,1-f ]purine-2,4(1H,3H)-dione (28). See ref 23.
1-(3-Chlorobenzyl)-3-(cyclopropylmethyl)-8-methoxypyrido[2,1-
f ]purine-2,4(1H,3H)-dione (29). See ref 23.
1-(4-Chlorobenzyl)-3-(cyclopropylmethyl)-8-methoxypyrido[2,1-
f ]purine-2,4(1H,3H)-dione (30). See ref 23.
3-(Cyclopropylmethyl)-1-(3,4-dichlorobenzyl)-8-methoxypyrido-
[2,1-f ]purine-2,4(1H,3H)-dione (31). See ref 23.
1-(4-Bromobenzyl)-3-(cyclopropylmethyl)-8-methoxypyrido[2,1-
f ]purine-2,4(1H,3H)-dione (32). White solid, 22 mg, 0.048 mmol,
yield 14%. 1H NMR (400 MHz, CDCl3) δ: 8.85 (d, J = 7.2 Hz, 1H),
7.46 (s, 4H), 6.99 (d, J = 1.6 Hz, 1H), 6.87 (dd, J = 7.2, 2.0 Hz, 1H),
5.33 (s, 2H), 3.99−3.85 (m, 5H), 1.34−1.24 (m, 1H), 0.50−0.44 (m,
4H) ppm. MS [ESI + H]+: calcd for C21H19N4O3, 454.06; found,
455.0.
3-(Cyclopropylmethyl)-8-methoxy-1-phenylethylpyrido[2,1-f ]-
purine-2,4(1H,3H)-dione (33). White solid, 112 mg, 0.29 mmol, yield
82%. 1H NMR (400 MHz, CDCl3) δ: 8.81 (d, J = 7.2 Hz, 1H), 7.35−
7.25 (m, 4H), 7.20 (t, J = 7.2 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.73
(dd, J = 7.2, 2.4 Hz, 1H), 4.40 (t, J = 8.0 Hz, 2H), 3.95−3.90 (m, 5H),
3.12 (t, J = 8.0 Hz, 2H), 1.32−1.23 (m, 1H), 0.49−0.40 (m, 4H) ppm.
MS [ESI + H]+: calcd for C22H22N4O3, 390.17; found, 391.0.
Biology. Chemicals and Reagents. [3H]8-Ethyl-4-methyl-2-
phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one26
([3H]34, speciﬁc activity 56 Ci·mmol−1) was a gift from Prof. C. E.
Müller (University of Bonn, Germany). Unlabeled 34 was purchased
from Tocris Ltd. (Abingdon, UK). 5′-N-Ethylcarboxamidoadenosine
(NECA) was purchased from Sigma-Aldrich (Steinheim, Germany).
Adenosine deaminase (ADA) was purchased from Boehringer
Mannheim (Mannheim, Germany). Bicinchoninic acid (BCA) and
BCA protein assay reagents were purchased from Pierce Chemical
Company (Rockford, IL, USA). Chinese hamster ovary cells stably
expressing the human adenosine A3 receptor (CHOhA3) were a gift
from Dr. K.-N. Klotz (University of Würzburg, Germany). All other
chemicals were obtained from standard commercial sources and were
of analytical grade.
Cell Culture and Membrane Preparation. Chinese hamster ovary
(CHO) cells, stably expressing the human adenosine A3 receptor
(CHOhA3), were cultured and membranes were prepared and stored
as previously described.44 Protein determination was done through use
of the bicinchoninic acid (BCA) method.45
Radioligand Displacement Assay. Membrane aliquots containing
∼15 μg of CHOhA3 protein were incubated in a total volume of 100
μL of assay buﬀer (50 mM Tris-HCl, 5 mM MgCl2, supplemented
with 0.01% CHAPS and 1 mM EDTA, pH 7.4) at 25 °C for 120 min.
Displacement experiments were performed using six concentrations of
competing antagonist in the presence of a ﬁnal concentration of ∼10
nM [3H] 34. At this concentration, total radioligand binding did not
exceed 10% of that added to prevent ligand depletion. Nonspeciﬁc
binding (NSB) was determined in the presence of 100 μM NECA.
Incubation was terminated by rapid ﬁltration performed on 96-well
GF/B ﬁlter plates (PerkinElmer, Groningen, The Netherlands), using
a PerkinElmer Filtermate harvester (PerkinElmer, Groningen, The
Netherlands). After drying the ﬁlter plate at 50 °C for 30 min, the
ﬁlter-bound radioactivity was determined by scintillation spectrometry
using the 2450 MicroBeta2 plate counter (PerkinElmer, Boston, MA).
Radioligand Association and Dissociation Assays. Association
experiments were performed by incubating membrane aliquots
containing ∼15 μg of CHOhA3 membrane in a total volume of 100
μL of assay buﬀer at 10 or 25 °C with ∼10 nM [3H] 34. The amount
of radioligand bound to the receptor was measured at diﬀerent time
intervals during a total incubation of 120 min. Dissociation
experiments were performed by preincubating membrane aliquots
containing ∼15 μg of protein in a total volume of 100 μL of assay
buﬀer at 10 or 25 °C for 60 min. After the preincubation, radioligand
dissociation was initiated by the addition of 5 μL of 100 μM unlabeled
NECA. The amount of radioligand still bound to the receptor was
measured at various time intervals for a total of 120 min to ensure that
full dissociation from hA3 receptor was reached. Incubations were
terminated and samples were obtained as described under Radioligand
Displacement Assay.
Radioligand Competition Association Assay. The binding kinetics
of unlabeled ligands were quantiﬁed using the competition association
assay based on the theoretical framework by Motulsky and Mahan.46
The competition association assay was initiated by adding membrane
aliquots (15 μg/well) at diﬀerent time points for a total of 240 min to
a total volume of 100 μL of assay buﬀer at 10 or 25 °C with ∼10 nM
[3H] 34 in the absence or presence of a single concentration of
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competing hA3R antagonists (i.e., at their IC50 value). Incubations
were terminated and samples were obtained as described under
Radioligand Displacement Assay. The “dual-point” competition
association assays were designed as described previously,27 where in
this case the two time points were selected at 20 (t1) and 240 min (t2).
[35S] GTPγS Binding Assay. The assays were performed by
incubating 15 μg of homogenized CHOhA3 membranes in a total
volume of 80 μL of assay buﬀer (50 mM Tris-HCl buﬀer, 5 mM
MgCl2, 1 mM EDTA, 0.05% BSA, and 1 mM DTT, pH 7.4)
supplemented with 1 μM GDP and 5 μg of saponin. The assays were
performed in a 96-well plate format, where DMSO stock solutions of
the compounds were added using a HP D300 Digital Dispenser
(Tecan, Man̈nedorf, Switserland). The ﬁnal concentration of organic
solvent per assay point was ≤0.1%. In all cases, the basal level of [35S]
GTPγS binding was measured in untreated membrane samples,
whereas the maximal level of [35S] GTPγS binding was measured by
treatment of the membranes with 10 μM 2-Cl-IBMECA. For the
insurmountability experiments, membrane preparations were preincu-
bated with or without antagonists (30-, 100-, 300-fold Ki values) for 60
min at 25 °C, prior to the addition of 2-Cl-IBMECA (10 μM to 0.1
nM) and 20 μL of [35S] GTPγS (ﬁnal concentration ∼0.3 nM), after
which incubation continued for another 30 min at 25 °C. For the
surmountability (control) experiments, antagonists and 2-Cl-IBMECA
were coincubated with [35S] GTPγS for 30 min at 25 °C. For all
experiments, incubations were terminated and samples were obtained
as described under Radioligand Displacement Assay by using GF/B
ﬁlters (Whatman International, Maidstone, UK).
Data Analysis. All experimental data were analyzed using the
nonlinear regression curve ﬁtting program GraphPad Prism 6.0
(GraphPad Software, Inc., San Diego, CA). From displacement assays,
IC50 values were obtained by nonlinear regression analysis of the
displacement curves. The obtained IC50 values were converted into Ki
values using the Cheng−Prusoﬀ equation to determine the aﬃnity of
the ligands.47 The observed association rates (kobs) derived from both
assays were obtained by ﬁtting association data using one phase
exponential association. The dissociation rates were obtained by ﬁtting
dissociation data to a one phase exponential decay model. The kobs
values were converted into association rate constants (kon) using the
equation kon = (kobs − koff)/[L], where [L] is the amount of
radioligand used for the association experiments. The association and
dissociation rates were used to calculate the kinetic KD using the
equation KD = koff/kon. Association and dissociation rate constants for
unlabeled compounds were calculated by ﬁtting the data into the
competition association model using “kinetics of competitive bind-
ing”:46
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where k1 is the kon of the radioligand (M
−1 s−1), k2 is the koff of the
radioligand (s−1), L is the radioligand concentration (nM), I is the
concentration of the unlabeled competitor (nM), X is the time (s), and
Y is the speciﬁc binding of the radioligand (DPM). The control curve
(without competitor) from competition association assays generates
the k1 value, and the k2 value was obtained from Radioligand
Association and Dissociation Assays. With that, the k3, k4 and Bmax can
be calculated, where k3 represents the kon (M
−1 s−1) of the unlabeled
ligand, k4 stands for the koff (s
−1) of the unlabeled ligand, and Bmax
equals the total binding (DPM). All competition association data were
globally ﬁtted. The residence time (RT, in min) was calculated using
the equation RT = 1/(60 × koff), as koff values are expressed in s
−1.
[35S] GTPγS binding curves were analyzed by nonlinear regression
using “log (agonist) vs response-variable slope” to obtain potency,
inhibitory potency, or eﬃcacy values of agonists and inverse agonists/
antagonists (EC50, IC50 or Emax, respectively). In the (in)-
surmountability assays, Gaddum/Schild EC50 shift equations were
used to obtain Schild-slopes and pA2 values; statistical analysis of two-
way ANOVA with Tukey’s post-test was applied. All experimental
values obtained are means of at least three independent experiments
performed in duplicate, unless stated otherwise. R2 and P values were
calculated using the GraphPad Prism linear regression analysis
function. Log P (log partition coeﬃcient) values were calculated
using Chemdraw Professional 15.0 (Cambridge Soft, PerkinElmer,
Waltham Mass).
Computational Studies. A ligand optimized homology model of
the hA3R was generated by following a similar approach as has been
used before48 and using the Maestro software package (Schroedinger
Inc., New York). In short: ﬁrst, diﬀerent homology models were
constructed based on the high resolution crystal structure of the
adenosine A2A receptor (PDB 4EIY)
41 and using a sequence alignment
from GPCRDB.49,50 In the subsequent steps, we iteratively optimized
the model using Prime.51−53 During every step, the best model was
selected based on enrichment (BEDROC-160.9 and ROC). For this,
we used a set of 100 diverse antagonists from ChEMBL54 obtained by
“Cluster Molecules”.55 We matched 50 decoys to every ligand
ionization state, using the DUD-e web service.56 The ﬁnal model
used here showed excellent enrichment (BEDROC-160.9, 0.55; ROC,
0.80). We introduced a long residence time ligand, 2, in the putative
ligand binding site using Induced ﬁt docking,57 with H-bond
constraints on Asn2506.55. On the basis of this, we generated a
WaterMap42,43 of the apo state of the receptor. Other ligands were
docked using core-constrained docking (using the core of 2 as
constraints). Figures were rendered using PyMol.58
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